← Klinické štúdie • Transplantácia obličky
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
Nábor prebieha
• Fáza 3 • intervenčná • NCT06830798
Stručný súhrn
The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.
Základné údaje
| Ochorenia | Delayed Graft Function, DGF, Kidney Transplant |
|---|---|
| Intervencie |
DRUG: Ravulizumab DRUG: Placebo |
| Sponzor | Alexion Pharmaceuticals, Inc. |
| Plánovaný počet | 450 |
| Začiatok | 2025-05-19 |
| Predp. ukončenie (primárne) | 2027-11-30 |
| Krajiny | United States, Argentina, Australia, Austria, Brazil, Canada, China, Czechia, France, Germany, Italy, Japan, Poland, Portugal, South Korea, Spain, Taiwan, United Kingdom |
| Posledná aktualizácia | 2026-06-18 |
Upozornenie: údaje sú orientačné a podliehajú zmenám. Úplné vstupné/vylučovacie
kritériá, kontakty a aktuálny stav nájdete v oficiálnom registri. Tento prehľad
nenahrádza lekársku konzultáciu.